In this issue of EuroIntervention

A mini focus on left main revascularisation with the IDEAL-LM trial; rationale and design of the ORBITA-2 trial; vessel FFR; a novel scoring tool for predicting the need for rotational atherectomy; outcomes of percutaneous vs surgical transaxillary TAVI; transcatheter mitral valve replacement with the Tendyne valve; ASD and PFO closure with a new bioresorbable transcatheter occluder; and more...

EuroIntervention 2022;17:.

Davide Capodanno
Davide Capodanno
I haven’t been back to the United States since 2020, before the pandemic and the start of all those restrictions on our freedom to travel. Anyone who has travelled in the last two years knows that every departure has seen an increase in the coefficient of logistical difficulty, taking into account COVID-19 testing, the online forms that need to be filled out, the printed ones you need to show and, in some cases, even the quarantine that needs to be foreseen. The restrictions, however, were not only practical but also psychological, given that, on top of all these travel ...

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

Read next article
In search of the "IDEAL" left main coronary stent and DAPT regimen

Latest news